Home > Dermatology > AAD 2022 > What’s Hot in Rare Diseases > JAK inhibition offers promising treatment prospects for uncommon dermatoses

JAK inhibition offers promising treatment prospects for uncommon dermatoses

Presented By
Prof. Matthew Vesely, Yale School of Medicine, USA
Conference
AAD 2022
Emerging data, often still in the form of case reports, demonstrated the efficacy of Janus kinase (JAK) inhibition in the treatment of diseases such as lichen planus, systemic sclerosis, and hidradenitis suppurativa (HS). JAK inhibition might become established as a treatment option for many more autoimmune and inflammatory skin conditions in the near future. The JAK/STAT pathway plays an important role in many autoimmune skin disorders that involve different immune response patterns mediated by diverse cytokines [1,2]. By now, the armamentarium of dermatologists has been amplified by various JAK inhibitors that have demonstrated efficacy in numerous dermatologic conditions [3]. These small molecules can target various downstream signalling cytokines that simultaneously contribute to a disease [4]. Currently, JAK inhibitors are also being investigated as a treatment for several diseases less common than psoriasis or atopic dermatitis. JAK1 ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on